Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'

Benzinga

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Viking Therapeutics . “This is a really fine company, and it will do well for multiple years because they have many ships coming in,” he added.

On Sept. 11, JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.

Gentex Corporation is “too closely related to autos, and autos have been hurt so bad. And I don't see a quick turn. We're going to need several Fed rate cuts before they turn,” Cramer said.

On July 26, the company reported second-quarter earnings per share of 37 cents, but it missed the street view of 52 cents. Quarterly sales of $572.93 million missed the analyst consensus of $622.79 million.

The Mad Money host said Cadre Holdings, Inc. is a “good simple story.”

On Aug. 9, Cadre Hldgs reported quarterly earnings of 31 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $144.31 million which beat the analyst consensus estimate of $142.05 million.

“Something's the matter with Celsius Holdings, Inc. ,” Cramer said. “I want to know what's wrong.”

On Sept. 19, Celsius Holdings appointed Hans Melotte to the company’s Board of Directors.

Price Action:

Viking shares gained 5.8% to settle at $68.16 on Thursday.
Gentex shares gained 1.8% to close at $29.82 during the session.
Cadre shares gained 2.4% to close at $37.36 during Thursday's session.
Celsius shares fell 0.6% to settle at $34.07 on Thursday.

Read Next:

Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Risk Disclosure

The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

Recent Searches

Top Searches

Markets

Analysis

User

24/7

Economic Calendar

Education

Data

Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'

Risk Disclosure